ALLMedicine™ Retinal Vein Occlusion Center

Mar 18th, 2023 - Satoyoshi syndrome is a rare systemic autoimmune disease that presents with painful muscle spasms. We report a case of impending central retinal vein occlusion (CRVO) secondary to granulomatous pan-uveitis in a 32-year-old woman with Satoyoshi syn...

Mar 14th, 2023 - Neovascular glaucoma (NVG) is a sight-threatening condition that is often refractory to treatment. Current management principles are yet to be standardized due to lack of evidence. We studied the interventions used to treat NVG at Sydney Eye Hospi...

Mar 14th, 2023 - Background Much confusion exists in the literature because central retinal vein occlusions and branch retinal vein occlusions (BRVOs) are often grouped and studied together. The natural history and the complication rate for each entity differ. The...

Mar 14th, 2023 - Background Much confusion exists in the literature because central retinal vein occlusions and branch retinal vein occlusions (BRVOs) are often grouped and studied together. The natural history and the complication rate for each entity differ. The...

Mar 14th, 2023 - Background Much confusion exists in the literature because central retinal vein occlusions and branch retinal vein occlusions (BRVOs) are often grouped and studied together. The natural history and the complication rate for each entity differ. The...

Mar 8th, 2023 - This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled, parallel-group study evaluating the efficacy, safety, and pharmacokinetics of faricimab administered by intravitreal (IVT) injection at 4-week intervals unt...

Mar 2nd, 2023 - Several studies tried to classify retinal ischemia due to retinal artery or vein occlusion into different grades. In some cases prognosis is dependent on grade of severity, especially in cases of retinal vein occlusion. State of the art to Diagnos...

Feb 28th, 2023 - This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled, parallel-group study evaluating the efficacy, safety, and pharmacokinetics of faricimab administered by intravitreal (IVT) injection at 4-week intervals unt...

Feb 24th, 2023 - Randomised, double-masked placebo controlled study to evaluate safety and proof of concept with ascending doses of ANXV (human recombinant Annexin A5 protein) during 5 consecutive days treatment in patients recently diagnosed with Retinal Vein Occ...

Feb 17th, 2023 - The primary objective is to assess the safety of intravitreal aflibercept injections in patients with wet age-related macular degeneration (wAMD), myopic choroidal neovascularization (mCNV), diabetic macular edema (DME), macular edema secondary to...

Oct 28th, 2022 - Note that some links may require subscriptions. Outpatient COVID treatment with nirmatrelvir-ritonavir (Paxlovid) was 36% and 30% lower for Black and Hispanic patients compared with white patients, a CDC report found. A high proportion of recovere...

Sep 27th, 2022 - Immunotherapy in the form of ipilimumab (Yervoy) plus nivolumab (Opdivo) followed by the targeted therapy combination encorafenib (Braftovi) plus binimetinib (Mektovi) elicited an overall survival (OS) benefit in patients with untreated BRAF-mutat...

Aug 3rd, 2022 - The FDA has approved the first interchangeable biosimilar to the ophthalmologic anti-VEGF agent ranibizumab (Lucentis), Coherus BioSciences announced. The approval of ranibizumab-eqrn (Cimerli) covers all five current FDA-approved indications for ...

Aug 2nd, 2022 - The menu of tissue-agnostic oncology drug approvals is growing, generating new treatment options for patients with rare cancers and strengthening the rationale for broad next-generation sequencing (NGS), experts say. In June 2022, the FDA approv...

Apr 18th, 2022 - (Reuters) - Patients with COVID-19 may have an increased risk of rare vision-threatening blood clots in the eye for months afterward, new findings suggest. Because SARS-CoV-2 infections increase the risk of blood vessel obstructions at other sites...